

Francesco Franchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1678711/publications.pdf>

Version: 2024-02-01

75
papers

3,407
citations

185998

28
h-index

143772

57
g-index

78
all docs

78
docs citations

78
times ranked

3521
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y ₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	1.1	366
2	Novel antiplatelet agents in acute coronary syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 30-47.	6.1	299
3	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
4	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
5	Impaired Responsiveness to the Platelet P2Y ₁₂ Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1005-1014.	1.2	155
6	Switching P2Y ₁₂ -receptor inhibitors in patients with coronary artery disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 11-27.	6.1	154
7	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Lancet, The</i> , 2021, 397, 1470-1483.	6.3	133
8	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1145-1154.	1.2	108
9	Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 139, 1661-1670.	1.6	106
10	Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1994-2004.	1.2	104
11	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 664-674.	2.3	94
12	Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2016, 134, 780-792.	1.6	82
13	Comparative effects of guided vs. potent P2Y ₁₂ inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. <i>European Heart Journal</i> , 2022, 43, 959-967.	1.0	79
14	Antithrombotic therapy for patients with STEMI undergoing primary PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 361-379.	6.1	76
15	Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1457-1467.	1.1	71
16	Institutional profile: University of Florida Health Personalized Medicine Program. <i>Pharmacogenomics</i> , 2017, 18, 421-426.	0.6	64
17	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 478-490.	1.6	61
18	Role of genetic testing in patients undergoing percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 151-164.	1.3	57

#	ARTICLE	IF	CITATIONS
19	Cangrelor: a review on pharmacology and clinical trial development. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1279-1291.	0.6	52
20	A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. <i>European Heart Journal</i> , 2016, 37, 2722-2730.	1.0	52
21	Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease. <i>Circulation</i> , 2018, 137, 2450-2462.	1.6	46
22	Diabetes and antiplatelet therapy: from bench to bedside. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 594-609.	0.7	45
23	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
24	Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. <i>Journal of the American College of Cardiology</i> , 2016, 67, 603-613.	1.2	41
25	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Translational Medicine</i> , 2018, 16, 92.	1.8	41
26	Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1089-1098.	1.1	35
27	Platelet Function Testing in Contemporary Clinical and Interventional Practice. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 300.	0.4	34
28	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y ₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e011139.	1.6	33
29	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	30
30	Pharmacodynamic Effects of Cangrelor on Platelet P2Y ₁₂ Receptor-Mediated Signaling in Prasugrel-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 426-434.	1.1	28
31	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 963-978.	1.3	27
32	Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1538-1549.	1.1	26
33	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 705-715.	2.3	25
34	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 267-277.	1.6	22
35	Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 083-093.	1.8	21
36	Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 133-138.	2.3	21

#	ARTICLE	IF	CITATIONS
37	Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. <i>JACC Basic To Translational Science</i> , 2020, 5, 419-428.	1.9	18
38	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. <i>Future Cardiology</i> , 2015, 11, 547-564.	0.5	17
39	Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 23-37.	1.0	17
40	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. <i>Expert Review of Hematology</i> , 2018, 11, 5-12.	1.0	17
41	Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 118-125.	1.0	15
42	Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001939.	1.2	15
43	<p>Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 217-226.	0.4	14
44	A Safety Evaluation of Cangrelor in Patients Undergoing PCI. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 275-285.	1.0	12
45	Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus. <i>JACC Basic To Translational Science</i> , 2019, 4, 763-775.	1.9	12
46	Defining the Link Between Chronic Kidney Disease, High Platelet Reactivity, and Clinical Outcomes in Clopidogrel-Treated Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002760.	1.4	11
47	Switching P2Y12 Receptor Inhibiting Therapies. <i>Interventional Cardiology Clinics</i> , 2017, 6, 67-89.	0.2	10
48	Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 1500-1502.	1.6	10
49	Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 741-747.	1.0	10
50	Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical and Translational Science</i> , 2020, 13, 473-481.	1.5	9
51	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. <i>Genetics in Medicine</i> , 2020, 22, 1898-1902.	1.1	9
52	Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. <i>Current Opinion in Cardiology</i> , 2014, 29, 553-563.	0.8	8
53	Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1060-1069.	1.8	8
54	In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1374-1375.	1.1	8

#	ARTICLE	IF	CITATIONS
55	The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1243-1245.	1.2	8
56	Clopidogrel drug interactions: a review of the evidence and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1079-1096.	1.5	8
57	Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 130-132.	1.1	7
58	Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization. <i>International Journal of Cardiology</i> , 2021, 345, 36-38.	0.8	7
59	Impact of the ABCD GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 146-155.	2.3	7
60	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 728-737.	1.4	6
61	Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1075-1083.	1.1	5
62	De-Escalation of Platelet P2Y12 Receptor Inhibiting Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2571-2573.	1.1	5
63	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1341-1351.	1.8	5
64	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 321-334.	2.3	3
65	Switching from ticagrelor to clopidogrel: New answers and further questions. <i>Thrombosis and Haemostasis</i> , 2017, 117, 207-208.	1.8	3
66	Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071986147.	1.1	3
67	Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 807-809.	1.1	3
68	Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 1301-1303.	1.6	2
69	Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 751-753.	1.1	2
70	Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 452-461.	1.4	2
71	Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 228-230.	1.1	1
72	Switching Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2342-2345.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Abstract 16668: The Effects of Dabigatran on Fibrin Network Structure and Lysis: A Simple Technique to Monitor Efficacy of Treatment?. Circulation, 2014, 130, .	1.6	0
74	Typical atrial flutter from blunt cardiac injury: an atypical cause. Journal of Geriatric Cardiology, 2021, 18, 155-157.	0.2	0
75	10â€¦Pharmacodynamic profiles of aspirin versus dual-pathway inhibition with either aspirin or clopidogrel among patients with stable atherosclerotic disease. European Heart Journal Supplements, 2021, 23, .	0.0	0